Ray of hope for advanced breast cancer patients: US approves new oral drug Inluriyo
The FDA has approved Inluriyo, a first-in-class oral therapy for ESR1-mutated advanced breast cancer, marking a significant breakthrough. This new drug targets hormone-resistant tumors by blocking estrogen receptors, reducing the risk of disease progression or death by 33-38%. Inluriyo offers a convenient pill alternative, bringing new hope to patients.
The FDA has approved Inluriyo, a first-in-class oral therapy for ESR1-mutated advanced breast cancer, marking a significant breakthrough. This new drug targets hormone-resistant tumors by blocking estrogen receptors, reducing the risk of disease progression or death by 33-38%. Inluriyo offers a convenient pill alternative, bringing new hope to patients.
